48 beagles and foxhounds of both sexes in wide weight and age ranges have been enrolled after clinical screening and examination.
The live phase of the study is expected to be completed late in the coming December quarter 2018.
CannPal's managing director Layton Mills said: “It is excellent to see the significant progress we are making with CPAT-01, and the quick turn-around time between phase Ia and phase IIb.
“CPAT-01 has the potential to offer a new solution for dogs that suffer from painful conditions and we look forward to rapidly progressing through phase II of this exciting research, at the completion of our phase I studies.”
Phase Ib is a continuation of the pharmacokinetic and safety study which started earlier in 2018 and showed excellent safety and tolerability for CPAT-01.
It builds on the pilot data already generated and includes additional endpoints.
Preparing for an application the FDA
With the results from these phase Ia and Ib studies, Cannpal plans to prepare to file an Investigational New Animal Drug (INAD) application with the US Food and Drug Administration (FDA).
It will also begin designing the protocol for the company’s pilot dose determination study to commence in the June half of 2019, which will include client-owned animals with osteoarthritis.
Last month, CannPal entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.
Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol treatment for epilepsy in dogs in 2019.